138 related articles for article (PubMed ID: 19669367)
1. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B.
Kobashi H; Fujioka S; Kawaguchi M; Kumada H; Yokosuka O; Hayashi N; Suzuki K; Okanoue T; Sata M; Tsubouchi H; Sato C; Kiyosawa K; Tanikawa K; Seriu T; Ishikawa H; Takaki A; Iwasaki Y; Osawa T; Takaki T; Sakaguchi K; Shiratori Y; Yamamoto K; Tenney DJ; Omata M
Hepatol Int; 2009 Jun; 3(2):403-10. PubMed ID: 19669367
[TBL] [Abstract][Full Text] [Related]
2. A case of entecavir resistance which is developed after complete viral suppression during entecavir treatment for nucleoside-naive chronic hepatitis B.
Doğan ÜB; Öztürk AB; Akın MS; Yalaki S; Sayan M
Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():206-9. PubMed ID: 25910308
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous emergence of entecavir resistance mutations in a nucleoside-naive chronic hepatitis B patient.
Lee HW; Kim HJ; Hong SP; Cha BK; Chang HY; Choi CH; Do JH; Kim JG; Chang SK
Intervirology; 2012; 55(5):380-4. PubMed ID: 22538265
[TBL] [Abstract][Full Text] [Related]
4. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
Colonno RJ; Rose R; Baldick CJ; Levine S; Pokornowski K; Yu CF; Walsh A; Fang J; Hsu M; Mazzucco C; Eggers B; Zhang S; Plym M; Klesczewski K; Tenney DJ
Hepatology; 2006 Dec; 44(6):1656-65. PubMed ID: 17133475
[TBL] [Abstract][Full Text] [Related]
5. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.
Tenney DJ; Rose RE; Baldick CJ; Pokornowski KA; Eggers BJ; Fang J; Wichroski MJ; Xu D; Yang J; Wilber RB; Colonno RJ
Hepatology; 2009 May; 49(5):1503-14. PubMed ID: 19280622
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis.
Rose RE; Hernandez D; Falk PJ; Ericson K; Zhou N; Thiry A; McPhee F
Hepatol Commun; 2018 Sep; 2(9):1123-1135. PubMed ID: 30202825
[TBL] [Abstract][Full Text] [Related]
7. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
Tenney DJ; Rose RE; Baldick CJ; Levine SM; Pokornowski KA; Walsh AW; Fang J; Yu CF; Zhang S; Mazzucco CE; Eggers B; Hsu M; Plym MJ; Poundstone P; Yang J; Colonno RJ
Antimicrob Agents Chemother; 2007 Mar; 51(3):902-11. PubMed ID: 17178796
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.
Mukaide M; Tanaka Y; Shin-I T; Yuen MF; Kurbanov F; Yokosuka O; Sata M; Karino Y; Yamada G; Sakaguchi K; Orito E; Inoue M; Baqai S; Lai CL; Mizokami M
Antimicrob Agents Chemother; 2010 Feb; 54(2):882-9. PubMed ID: 19933798
[TBL] [Abstract][Full Text] [Related]
9. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
Walsh AW; Langley DR; Colonno RJ; Tenney DJ
PLoS One; 2010 Feb; 5(2):e9195. PubMed ID: 20169198
[TBL] [Abstract][Full Text] [Related]
11. CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.
Higashi-Kuwata N; Hayashi S; Das D; Kohgo S; Murakami S; Hattori SI; Imoto S; Venzon DJ; Singh K; Sarafianos SG; Tanaka Y; Mitsuya H
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670420
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of lamivudine plus adefovir combination therapy and entecavir monotherapy for chronic hepatitis B patients].
Yu JH; Shi JP; Wu J; Li XO; Guo JC; Xun YH; Zhao C; Jin J; Xu AF; Lou GQ
Zhonghua Gan Zang Bing Za Zhi; 2011 Feb; 19(2):88-92. PubMed ID: 21492508
[TBL] [Abstract][Full Text] [Related]
13. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
Shi H; Han Z; Liu J; Xue J; Zhang S; Zhu Z; Xia J; Huang M
Med Sci Monit; 2017 Nov; 23():5230-5236. PubMed ID: 29095799
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
15. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice.
Liu Y; Zhou Y; Li X; Niu M; Chen R; Shao J; Si L; Luo D; Lin Y; Li L; Zhang K; Xiao X; Xu Z; Liu M; Lu M; Zoulim F; Xu D
Emerg Microbes Infect; 2019; 8(1):354-365. PubMed ID: 30866789
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
Lee KS; Kweon YO; Um SH; Kim BH; Lim YS; Paik SW; Heo J; Lee HJ; Kim DJ; Kim TH; Lee YS; Byun KS; Kim D; Lee MS; Yu K; Suh DJ
Clin Mol Hepatol; 2017 Dec; 23(4):331-339. PubMed ID: 28946736
[TBL] [Abstract][Full Text] [Related]
18. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
[TBL] [Abstract][Full Text] [Related]
19. Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy.
Li X; Jie Y; You X; Shi H; Zhang M; Wu Y; Lin G; Li X; Gao Z; Chong Y
Int J Clin Exp Med; 2015; 8(11):21062-70. PubMed ID: 26885037
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
